News

Pharmaceutical Product Development, LLC (PPD) announced it was awarded a seven-year contract under the Clinical Research Support Services (CRSS) program of the Division of AIDS (DAIDS),…
Read More...

Aviragen Therapeutics and Vaxart announced that the companies have entered into a definitive merger agreement. The merger will result in a combined company, Vaxart, Inc., focused on…
Read More...

Abbott has secured U.S. Food and Drug Administration (FDA) 510(k) clearance for its Alinity™ ci-series instruments for clinical chemistry and immunoassay diagnostics. These innovative…
Read More...

AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, announced that the US Food and Drug Administration (FDA) has granted accelerated approval…
Read More...

Medicure International has acquired an exclusive license to sell and market PREXXARTAN (valsartan) oral solution in the United States and its territories from Carmel Biosciences, Inc.…
Read More...

MilliporeSigma today announced the signing of a Memorandum of Understanding (MoU) with Samsung BioLogics for a strategic alliance on biopharmaceutical manufacturing and biologics…
Read More...

Novartis announced that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have signed an option agreement for future strategic collaboration and licensing to…
Read More...

Mustang Bio announced that it has entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the clinical…
Read More...

CMP Pharma announced that CaroSpir® (Spironolactone Oral Suspension, 25 mg/5 mL), the first and only FDA-approved oral liquid dosage form of the potassium-sparing diuretic…
Read More...

Incyte Corporation and MedImmune, AstraZeneca’s  global biologics research and development arm, announced the expansion of their clinical collaboration. As part of the agreement, the…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted Bayer's Biologics License Application (BLA) filing for BAY94-9027, an extended half-life site-specifically PEGylated recombinant…
Read More...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the pivotal phase 3 placebo-controlled ENLIVEN (NCT02371369) study of pexidartinib met its primary…
Read More...

Novartis announced that the company has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Kymriah™ (tisagenlecleucel)…
Read More...

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Alprolix (eftrenonacog alfa), for the…
Read More...

AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH)…
Read More...

Charles River Laboratories International, Inc. announced its partnership with InSphero AG, a leading supplier of 3D solutions for in vitro drug discovery and development. Through…
Read More...

Zydus Cadila has received the final approval from the USFDA to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base). The drug is indicated to treat…
Read More...

Lannett Company, Inc. announced that it has entered into a settlement and license agreement with Celgene Corporation that resolves patent infringement litigation in the U.S. related to…
Read More...

Xynomic Pharma announced that it has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from Boehringer Ingelheim, a…
Read More...